Truist Securities Reiterates Buy Rating on CorMedix (CRMD)
Tweet Send to a Friend
Truist Securities analyst Les Sulewski reiterated a Buy rating and $16.00 price target on CorMedix (NASDAQ: CRMD)The analyst commented, "CRMD ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
